Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35798016

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Aug
First author
Kelley RK

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Aug;23(8):962-963. doi: 10.1016/S1470-2045(22)00383-7.
    note
    Source null
    related pmid
    35798015
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Oct;23(10):e441. doi: 10.1016/S1470-2045(22)00497-1.
    note
    Source null
    related pmid
    36174622
    relationship
    Comment in
  3. citation
    Ann Transl Med. 2024 Aug 1;12(4):59. doi: 10.21037/atm-23-421.
    note
    Source null
    related pmid
    39118945
    relationship
    Comment in

Authors and identifiers

  1. name
    Kelley RK
    type
    Author
  2. name
    Rimassa L
    type
    Author
  3. name
    Cheng AL
    type
    Author
  4. name
    Kaseb A
    type
    Author
  5. name
    Qin S
    type
    Author
  6. name
    Zhu AX
    type
    Author
  7. name
    Chan SL
    type
    Author
  8. name
    Melkadze T
    type
    Author
  9. name
    Sukeepaisarnjaroen W
    type
    Author
  10. name
    Breder V
    type
    Author
  11. name
    Verset G
    type
    Author
  12. name
    Gane E
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kelley RK
    type
    Author
  2. name
    Rimassa L
    type
    Author
  3. name
    Cheng AL
    type
    Author
  4. name
    Kaseb A
    type
    Author
  5. name
    Qin S
    type
    Author
  6. name
    Zhu AX
    type
    Author
  7. name
    Chan SL
    type
    Author
  8. name
    Melkadze T
    type
    Author
  9. name
    Sukeepaisarnjaroen W
    type
    Author
  10. name
    Breder V
    type
    Author
  11. name
    Verset G
    type
    Author
  12. name
    Gane E
    type
    Author
bibliography ids
  1. nci-bib-631ec2e7363d27afd7a6ad82
book metadata
content sha256
9420a67ff70e376ca6daa71be8bae7e5df4e0f8e341364f275225e0ee51b67b9
document type
citation
dois
  1. 10.1016/S1470-2045(22)00326-6
electronic publication date
display
2022 Jul 4
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35798016
immutable id
pubmed:35798016@9420a67ff70e376ca6daa71be8bae7e5df4e0f8e341364f275225e0ee51b67b9
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
8
name
The Lancet. Oncology
nlm unique id
100957246
pages
995-1008
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Aug;23(8):962-963. doi: 10.1016/S1470-2045(22)00383-7.
    note
    Source null
    related pmid
    35798015
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Oct;23(10):e441. doi: 10.1016/S1470-2045(22)00497-1.
    note
    Source null
    related pmid
    36174622
    relationship
    Comment in
  3. citation
    Ann Transl Med. 2024 Aug 1;12(4):59. doi: 10.21037/atm-23-421.
    note
    Source null
    related pmid
    39118945
    relationship
    Comment in
outcomes validated
false
pmid
35798016
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
b806450ec7bcc3a8775257e1f358c40610e35bb8f196d7896efbbce35397256c
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Aug
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35798016/
title
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice